BioSpace News Archive

OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix™ HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures.

VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces presentation of a poster at the European Network to Cure ALS (ENCALS) Annual Meeting at the University of Edinburgh on 1-3 June, 2022.

New Study from Seraphina Therapeutics Finds that a Good Saturated Fat, C15:0, is Better, Broader and Safer than Omega-3.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual and special meeting of shareholders held on May 26, 2022 (the “Meeting”), which included the election as directors of the Company of all of the nominees listed in its management information and proxy circular dated April 14, 2022 (the “Information Circular”).

Y-mAbs Therapeutics, Inc. announced that Dr. Shakeel Modak, MD from Memorial Sloan Kettering will present results from the naxitamab-based chemoimmunotherapy trial in patients with chemoresistant high-risk neuroblastoma, at the American Society of Clinical Oncology Annual Meeting to be held June 3-7, 2022.

Yingli Pharma US, Inc, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027 a potent and selective TGFβ receptor 1 (TGFβR1) inhibitor.

Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Company management will participate in two upcoming investor conferences in June 2022.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the following investor conferences.

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the LD Micro Invitational Conference.

At the 69th Annual Conference of the Israel Heart Society, UltraSight, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.